Past Updates

In this supplement we added new stability information to the monographs for ACYCLOVIR SODIUM, CEFIDEROCOL SULFATE TOSYLATE, FLUOROURACIL, GANCICLOVIR SODIUM, INSULIN, REGULAR, MEROPENEM, PEMETREXED, and PHLOROGLUCINOL DIHYDRATE.

New compatibility information was added to the existing drug monographs for AMOXICILLIN SODIUM, AMPHOTERICIN B LIPOSOME, BUPIVACAINE HYDROCHLORIDE, CEFAZOLIN SODIUM, CEFEPIME HYDROCHLORIDE, CO-TRIMOXAZOLE, DAPTOMYCIN, DILTIAZEM HYDROCHLORIDE, HEPARIN SODIUM, INSULIN, REGULAR, KETOROLAC TROMETHAMINE, LEVETIRACETAM, LEVOFLOXACIN, MAGNESIUM SULFATE, PANTOPRAZOLE SODIUM, PYRIDOXINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE, VORICONAZOLE, and POSACONAZOLE with 19 other drugs.

In this Supplement we added a new monograph for ANGIOTENSIN II. 

We also added new stability information to the monograph for BEVACIZUMAB. 

New compatibility information was added to the existing drug monographs for FLUCONAZOLE, MANNITOL, MOXIFLOXACIN HYDROCHLORIDE, NOREPINEPHRINE BITARTRATE, PIPERACILLIN AND TAZOBACTAM, TOTAL PARENTERAL NUTRITION SOLUTIONS, and SILDENAFIL CITRATE with 43 other drugs.

In this update we added a new monograph for DURVALUMAB.

We also added new stability information to the monographs for CARMUSTINE, CETUXIMAB, CISATRACURIUM BESYLATE, MITOMYCIN, PEMETREXED, and THIOTEPA.

New compatibility information was added to the existing drug monographs for ALPROSTADIL, AMPICILLIN SODIUM, AMPICILLIN SODIUM – SULBACTAM SODIUM, BUMETANIDE, CEFOTAXIME SODIUM, CEFTRIAXONE, DEXMEDETOMIDINE HYDROCHLORIDE, DIHYDROERGOTAMINE MESYLATE, DOPAMINE HYDROCHLORIDE, FUROSEMIDE, HEPARIN SODIUM, HYDROMORPHONE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE, LACOSAMIDE, MORPHINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE, POTASSIUM CHLORIDE, ROCURONIUM BROMIDE, SILDENAFIL CITRATE, TOTAL PARENTERAL NUTRITION SOLUTIONS, VANCOMYCIN HYDROCHLORIDE, and VASOPRESSIN.

In this update we added a new monograph for REMDESIVIR.

We also added new stability information to the monographs for EPINEPHRINE HYDROCHLORIDE and REMDESIVIR.

New compatibility information was added to the existing drug monograph FOR ALPROSTADIL, AMPICILLIN SODIUM, AMPICILLIN SODIUM – SULBACTAM SODIUM, BUMETANIDE, CEFEPIME HYDROCHLORIDE, CISATRACURIUM BESYLATE, DEXMEDETOMIDINE HYDROCHLORIDE, EPINEPHRINE HYDROCHLORIDE, FENTANYL CITRATE, FUROSEMIDE, HEPARIN SODIUM, HYDROMORPHONE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE, MORPHINE SULFATE, OCTREOTIDE ACETATE, PIPERACILLIN AND TAZOBACTAM, SILDENAFIL CITRATE, TOTAL PARENTERAL NUTRITION SOLUTIONS, VANCOMYCIN HYDROCHLORIDE, and VASOPRESSIN.

In this update we added a new monograph for SULBACTAM AND DURLOBACTAM.

We also added new stability information to the monographs for OMADACYCLINE.

New compatibility information was added for SULBACTAM AND DURLOBACTAM in combination with 95 different drugs.

In this update we added a new monograph for NUTRILIPID.

We also added new stability information to the monographs for FAT EMULSION, NUTRILIPID, NOREPINEPHRINE BITARTRATE and TRACE ELEMENT SOLUTION.

New compatibility information was added to the existing drug monographs for FAT EMULSION with 36 different drugs; INTRALIPID, NUTRILIPID, and SMOFLIPID, each with 17 different drugs; TOTAL PARENTERAL NUTRITION SOLUTIONS, TRACE ELEMENT SOLUTION, and VALPROATE SODIUM.

In this update we added new monographs for MOGAMULIZUMAB-KPKC and REMIMAZOLAM BESYLATE.

We also added new stability information to the monographs for ASPARAGINASE, BEVACIZUMAB, DEXCHLORPHENIRAMINE MALEATE, FERRIC CARBOXYMALTOSE, IDARUBICIN HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE, VASOPRESSIN, and VORICONAZOLE.

New compatibility information was added to the existing drug monographs for CALCIUM CHLORIDE, DEFIBROTIDE SODIUM, DEXMEDETOMIDINE HYDROCHLORIDE, EPINEPHRINE HYDROCHLORIDE, FENTANYL CITRATE, FUROSEMIDE, HEPARIN SODIUM, REMIFENTANIL HYDROCHLORIDE, and REMIMAZOLAM BESYLATE with six other drugs.

In this update we added a new monograph for LACOSAMIDE.

We also added new stability information to the monographs for ASCORBIC ACID, CONJUGATED ESTROGENS, LEVOLEUCOVORIN CALCIUM, SODIUM BICARBONATE, and THIAMINE HYDROCHLORIDE.

New compatibility information was added to the existing drug monographs for CYTARABINE, DEXAMETHASONE SODIUM PHOSPHATE, METHOTREXATE, METHYLPREDNISOLONE SODIUM SUCCINATE, ONDANSETRON HYDROCHLORIDE, and DEXMEDETOMIDINE with twenty-three other drugs.

In this update we added a new monograph for TOCILIZUMAB.

We also added new stability information to the monographs for DIGOXIN, HYDROMORPHONE HYDROCHLORIDE, MORPHINE HYDROCHLORIDE, SODIUM CHLORIDE, and VANCOMYCIN HYDROCHLORIDE.

New compatibility information was added to the existing drug monograph for AMPHOTERICIN B, BUMETANIDE, FOSFOMYCIN DISODIUM, PLAZOMICIN, SCOPOLAMINE HYDROBROMIDE, and IMIPENEM, CILASTATIN AND RELEBACTAM with 28 other drugs.

In this update we added a new monograph for MARGETUXIMAB-CMKB and METHYLPHENIDATE HYDROCHLORIDE.

We also added new stability information to the monographs for CEFTOLOZANE AND TAZOBACTAM, CEFUROXIME SODIUM, FILGRASTIM, INSULIN ASPART, INSULIN GLULISINE, INSULIN LISPRO, LEVETIRACETAM, PIPERACILLIN AND TAZOBACTAM, and VANCOMYCIN HYDROCHLORIDE.

New compatibility information was added to the existing drug monograph for IMIPENEM, CILASTATIN, and RELEBACTAM with 52 other drugs.

In this update we added a new monograph for FOSDENOPTERIN HYDROBROMIDE.

We also added new stability information to the monographs for DOBUTAMINE HYDROCHLORIDE, IRON DEXTRAN, and ZICONOTIDE.

New compatibility information was added to the existing drug monograph for CEFIDEROCOL SULFATE TOSYLATE with 91 different parenteral drugs.

In this update we added a new monograph for CASIMERSEN.

We also added new stability information for for AMPICILLIN SODIUM and INSULIN, REGULAR.

New compatibility information was added to these existing drug monographs: MEROPENEM with 101 other drugs, TOTAL PARENTERAL NUTRITION SOLUTIONS, and VORICONAZOLE.

In this update we added new monographs for ATEZOLIZUMAB and TRILACICLIB.

We also added new stability information to COVID-19 VACCINE, mRNA, and to 48 other existing drug monographs.

New compatibility information was added to these existing drug monographs: CEFEPIME HYDROCHLORIDE, CISATRACURIUM BESYLATE, DEXMEDETOMIDINE HYDROCHLORIDE, FENTANYL CITRATE, FOSPHENYTOIN, LEVETIRACETAM, NALOXONE HYDROCHLORIDE, NOREPINEPHRINE BITARTRATE, PIPERACILLIN AND TAZOBACTAM, PROPOFOL, VANCOMYCIN HYDROCHLORIDE, and VASOPRESSIN.

In this update we added new monographs for ANSUVIMAB-ZYKL, IBUPROFEN LYSINE, OLICERIDINE, and SETMELANOTIDE.

We also added new stability information to these existing drug monographs: IDARUBICIN HYDROCHLORIDE, MEROPENEM, PIPERACILLIN AND TAZOBACTAM, and TRASTUZUMAB.

New compatibility information was added to these existing drug monographs: ACETAMINOPHEN with 12 other drugs; CLONIDINE HYDROCHLORIDE, IBUPROFEN LYSINE with 20 other drugs; LEVOBUPIVACAINE; MEROPENEM; MORPHINE HYDROCHLORIDE; RIFAMPIN, ROPIVACAINE HYDROCHLORIDE, SUFENTANIL; and TEDIZOLID PHOSPHATE.

In this update we added new monographs for for COVID-19 VACCINE (JANSSEN), TAFASITAMAB-CXIX, and VILTOLARSEN.

We also added new stability information to these existing drug monographs:  AMIODARONE HYDROCHLORIDE, AZTREONAM, CEFEPIME HYDROCHLORIDE, CEFTAZIDIME, COVID-19 VACCINE (PFIZER-BIONTECH), IMIPENEM-CILASTATIN, ISOSORBIDE DINITRATE, KETAMINE HYDROCHLORIDE, LORAZEPAM, MEROPENEM, PIPERACILLIN AND TAZOBACTAM, and VALPROATE SODIUM.

New compatibility information was added to these existing drug monographs: ALPROSTADIL, CALCIUM GLUCONATE, CEFAZOLIN SODIUM, CEFTAZIDIME, CISATRACURIUM BESYLATE, DEXMEDETOMIDINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE, EPINEPHRINE HYDROCHLORIDE, FUROSEMIDE, GENTAMICIN SULFATE, INSULIN, REGULAR, TRAMADOL HYDROCHLORIDE, KETAMINE HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE, MILRINONE HYDROCHLORIDE, NOREPINEPHRINE BITARTRATE, ONDANSETRON HYDROCHLORIDE, PERITONEAL DIALYSIS SOLUTIONS, and VANCOMYCIN HYDROCHLORIDE.

In this Supplement we added new monographs for COVID-19 VACCINE, EPTINEZUMAB-JJMR; IMIPENEM, CILASTATIN, AND RELEBACTAM; and SACITUZUMAB GOVITECAN-HZIY.

We also added new stability information to these existing drug monographs:  FOSPHENYTOIN SODIUM, METHADONE HYDROCHLORIDE, and MILRINONE LACTATE.

New compatibility information was added to these existing drug monographs: ALPROSTADIL, AMIODARONE HYDROCHLORIDE, BUMETANIDE, DEXMEDETOMIDINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE, EPINEPHRINE HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE, FENTANYL CITRATE, FUROSEMIDE, HEPARIN SODIUM, MILRINONE LACTATE, NICARDIPINE HYDROCHLORIDE, NITROPRUSSIDE SODIUM, TOTAL PARENTERAL NUTRITION SOLUTIONS, VASOPRESSIN; and IMIPENEM, CILASTATIN, AND RELEBACTAM with nine different parenteral drugs.

In this Supplement we added new monographs for CIFIDEROCOL SULFATE TOSYLATE, ISATUXIMAB, and SMOFLIPID.

We also added new stability information to these existing drug monographs: ACYCLOVIR SODIUM, AMIODARONE HYDROCHLORIDE, AMOXACILLIN SODIUM, AMPICILLIN SODIUM, AZTREONAM, BORTEZOMIB, BUSULFAN, CEFEPIME HYDROCHLORIDE, CEFTRIAXONE SODIUM, CIPROFLOXACIN, CISATRACURIUM BESYLATE, CYTARABINE, GENTAMICIN SULFATE, HEPARIN SODIUM, HYDROCORTISONE SODIUM SUCCINATE, KETAMINE HYDROCHLORIDE, LEVOFLOXACIN, MEROPENEM, MORPHINE SULFATE, TOBRAMYCIN SULFATE, and VANCOMYCIN HYDROCHLORIDE.

New compatibility information was added to these existing drug monographs: ACETAMINOPHEN, ALBUMIN, HUMAN SERUM, BUSULFAN, CEFEPIME HYDROCHLORIDE, CEFTOLOZANE AND TAZOBACTAM, CIPROFLOXACIN, CISATRACURIUM BESYLATE, DORIPENEM, EPINEPHRINE HYDROCHLORIDE, ESOMEPRAZOLE SODIUM, FLUDARABINE PHOSPHATE, HYDROCORTISONE SODIUM SUCCINATE, IBUPROFEN, LEVOFLOXACIN, LEVOTHYROXINE SODIUM, MEROPENEM, and NOREPINEPHRINE BITARTRATE.

In this update we added a new monograph for FERRIC DERISOMALTOSE.

We also added new stability information to these existing drug monographs: ASCORBIC ACID, CALCIUM GLUCONATE, CLONIDINE HYDROCHLORIDE, CLOXACILLIN SODIUM, ETOPOSIDE, LORAZEPAM, MAGNESIUM SULFATE, MIDAZOLAM HYDROCHLORIDE, MILRINONE LACTATE, PHYTONADIONE, and VANCOMYCIN HYDROCHLORIDE.

In addition, new compatibility information is reported for these drugs: BACLOFEN, CALCIUM CHLORIDE, CALCIUM GLUCONATE, DOPAMINE HYDROCHLORIDE, NITROPRUSSIDE SODIUM, ROPIVACAINE HYDROCHLORIDE, SUFENTANIL CITRATE, TOTAL PARENTERAL NUTRITION SOLUTIONS, and TREPROSTINIL SODIUM.

In this Supplement we added a new monograph for GLUCAGON.

We also added new stability information to these existing drug monographs: ALPROSTADIL, ALTEPLASE, CEFOTAXIME, CEFTOLOZANE AND TAZOBACTAM, COLISTIMETHATE SODIUM, DIAZEPAM, FLUOROURACIL, IBUPROFEN, ISOSORBIDE DINITRATE, MEROPENEM AND VABORBACTAM, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, NOREPINEPHRINE BITARTRATE, TORSEMIDE, VANCOMYCIN HYDROCHLORIDE, and VORICONAZOLE.

In addition, new compatibility information is reported for these drugs: CIPROFLOXACIN, FUROSEMIDE, IBUPROFEN, INSULIN, REGULAR, KETAMINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE, LINEZOLIDE, MEROPENEM, PERITONEAL DIALYSIS SOLUTIONS, PROPOFOL, REMIFENTANIL HYDROCHLORIDE, TOTAL PARENTERAL NUTRITION SOLUTIONS, and VANCOMYCIN HYDROCHLORIDE.

We added new stability information to these existing drug monographs: BUPRENORPHINE HYDROCHLORIDE, CEFUROXIME SODIUM, DIPHENHYDRAMINE HYDROCHLORIDE, ERAVACYCLINE, and FUROSEMIDE.

In addition, new compatibility information is reported for ERAVACYCLINE with 51 other drugs.

In this supplement we added a new drug monograph for LEVOSIMENDAN, NATALIZUMAB, NIVOLUMAB, NUSINERSEN, OCRELIZUMAB, OMADACYCLINE, PEMBROLIZUMAB, and VEDOLIZUMAB.

We added new stability information to these existing drug monographs: AMIFOSTINE, AMINOPHYLLINE, BUPIVACAINE HYDROCHLORIDE, CARBOPLATIN, CHLORAMPHENICOL SODIUM SUCCINATE, CEFOTETAN DISODIUM, CORTICOTROPIN, TRASTUZUMAB, and VALPROATE SODIUM.

In addition, new compatibility information is reported for these drugs: DOBUTAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE, EPINEPHRINE HYDROCHLORIDE, FENTANYL CITRATE, MIDAZOLAM HYDROCHLORIDE, MILRINONE LACTATE, NITROGLYCERINE, NITROPRUSSIDE SODIUM, NOREPINEPHRINE BITARTRATE, REMIFENTANIL HYDROCHLORIDE, ROCURONIUM BROMIDE, SODIUM THIOSULFATE, VASOPRESSIN, and VECURONIUM BROMIDE.

In this update we added a new drug monograph for DALBAVANCIN.

We added new stability information to the existing drug monographs for AMIODARONE HYDROCHLORIDE, CARBOPLATIN, CEFAZOLIN SODIUM, CEFTAZIDIME, INFLIXIMAB, MEROPENEM, METHOTRIMEPRAZINE HYDROCHLORIDE, PIPERACILLIN and TAZOBACTAM, AND SODIUM THIOSULFATE.

In addition, new compatibility information is reported for these drugs:  ACETAMINOPHEN, AMPICILLIN SODIUM, AMPICILLIN SODIUM – SULBACTAM SODIUM, BLINATUMOMAB, CEFTAZIDIME, CLINDAMYCIN PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE, DOXORUBICIN HYDROCHLORIDE, ETOPOSIDE PHOSPHATE, FENTANYL CITRATE, FOSPHENYTOIN SODIUM, FUROSEMIDE, HALOPERIDOL LACTATE, HYDROMORPHONE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE, KETOPROFEN, LIDOCAINE HYDROCHLORIDE, MAGNESIUM SULFATE, METRONIDAZOLE HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE, RASBURICASE, SUGAMMADEX, TOTAL PARENTERAL NUTRITION SOLUTIONS, VINCRISTINE SULFATE, and VORICONAZOLE.

In this supplement we added a new drug monograph for PLAZOMICIN.

We added new stability information for the existing drug monographs for AMIODARONE HYDROCHLORIDE, BORTEZOMIB, CISPLATIN, NOREPINEPHRINE BITARTRATE, PEMETREXED, RITUXIMAB, and VANCOMYCIN HYDROCHLORIDE.

In addition, new compatibility information is reported for these existing monographs: CEFTRIAXONE SODIUM, LEVOFLOXACIN, and MILRINONE LACTATE, plus PLAZOMICIN with 92 other drugs.

In this update we added new drug monographs for FOSFOMYCIN DISODIUM and ISONIAZID.

We added new stability information for the existing drug monographs for ADENOSINE, MILRINONE LACTATE, and PROPOFOL.

In addition, new compatibility information is reported for these existing monographs: CLONIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE, HEPARIN SODIUM, KETAMINE HYDROCHLORIDE, LEVETIRACETAM, MICAFUNGIN SODIUM, MIDAZOLAM HYDROCHLORIDE, PROPOFOL, REMIFENTANIL HYDROCHLORIDE, SODIUM BICARBONATE, and SUFENTANIL CITRATE; and for FOSFOMYCIN DISODIUM with 95 different drugs.

In this supplement we added a new drug monograph for PLERIXAFOR with new stability and compatibility information.

We added new stability information for the existing drug monographs for DECITABINE MESYLATE, EPINEPHRINE HYDROCHLORIDE, MEROPENEM AND VABORBACTAM, NOREPINEPHRINE BITARTRATE, OXALIPLATIN, ROLAPITANT HYDROCHLORIDE, and VALPROATE SODIUM.

In addition, new compatibility information is reported for these existing monographs: BACLOFEN, DEXAMETHASONE SODIUM PHOSPHATE, MORPHINE SULFATE, PALONOSETRON HYDROCHLORIDE, ROLAPITANT HYDROCHLORIDE, and MEROPENEM AND VABORBACTAM with 88 different drugs.

In this supplement we added a new drug monograph for ROLAPITANT HYDROCHLORIDE and provided new stability and compatibility information.

We added new stability information for the existing drug monographs for AZACITIDINE, BUSULFAN, DALTEPARIN SODIUM, DEXMEDETOMIDINE HYDROCHLORIDE, EPINEPHRINE HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE, NOREPINEPHRINE BITARTRATE, and PROCAINAMIDE HYDROCHLORIDE.

In addition, new compatibility information is reported for these existing monographs: DEXAMETHASONE SODIUM PHOSPHATE, GENTAMICIN SULFATE, GRANISETRON HYDROCHLORIDE, HEPARIN SODIUM, PALONOSETRON HYDROCHLORIDE, SODIUM CITRATE, VANCOMYCIN; and BLINATUMOMAB with 39 other drugs.

In this supplement we added new stability information for the existing drug monograph for TENECTEPLASE. In addition, new compatibility information is reported for these existing monographs:  MORPHINE SULFATE, ROPIVACAINE HYDROCHLORIDE, and ZICONOTIDE; COLISTIMETHATE SODIUM WITH ERTAPENEM, IMIPENEM-CILASTATIN SODIUM, LINEZOLID, MEROPENEM, PIPERACILLIN AND TAZOBACTAM, and VANCOMYCIN HYDROCHLORIDE; and ISAVUCONAZONIUM SULFATE with 95 other drugs.

In this supplement we added new stability information for these existing drug monographs: ALPROSTADIL, METHOTREXATE, and SILDENAFIL CITRATE.
In addition, new compatibility information is reported for over 100 existing drug monographs, including entries for CEFTOLOZANE and TAZOBACTAM with 95 other drugs, CEFTAZIDIME AND AVIBACTAM, DOPAMINE HYDROCHLORIDE, HEPARIN SODIUM, PIPERACILLIN AND TAZOBACTAM, SILDENAFIL CITRATE, and VANCOMYCIN HYDROCHLORIDE.

In this supplement we added new stability information for these existing drug monographs: BUSULFAN, CARBOPLATIN, CISPLATIN, CLADRIBINE, CYTARABINE, DACARBAZINE, DACTINOMYCIN, DOPAMINE HYDROCHLORIDE, EPINEPHRINE HYDROCHLORIDE, HYDROCORTISONE SODIUM PHOSPHATE, IDARUBICIN HYDROCHLORIDE, IFOSFAMIDE, METHOTREXATE, MITOMYCIN, MITOXANTRONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE, PENTOSTATIN, TOPOTECAN HYDROCHLORIDE, VINBLASTINE SULFATE, VINCRISTINE SULFATE, and VINORELBINE TARTRATE.

In addition new compatibility information is reported for over 40 existing drug monographs, including entries for PIPERACILLIN AND TAZOBACTAM with VANCOMYCIN HYDROCHLORIDE, ABCIXIMAB with six other drugs, CLONAZEPAM with six other drugs, HALOPERIDOL LACTATE with thirteen other drugs, OMEPRAZOLE HYDROCHLORIDE with five other drugs, and TIROFIBAN HYDROCHLORIDE with seven other drugs.

In this supplement we added new drug monographs with stability and compatibility data for these drugs: BLINATUMOMAB, BRIVARACETAM, ERIBULIN MESYLATE, FERRIC CARBOXYMALTOSE, DECITABINE, FOMEPIZOLE, GLOBULIN, IMMUNE (HUMAN) AND HYALURONIDASE, IBANDRONATE SODIUM, IDARUCIZUMAB, ISAVUCONAZONIUM SULFATE, RASBURICASE, SODIUM FERRIC GLUCONATE COMPLEX, SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE, SODIUM NITRITE, TEMOZOLOMIDE, VINCRISTINE SULFATE LIPOSOME, and ZOLEDRONIC ACID.

Also, we added new stability information for these existing drug monographs: AZTREONAM, BACLOFEN, BUSULFAN, CARBOPLATIN, CEFPIROME SULFATE, CEFEPIME HYDROCHLORIDE, CEFTAZIDIME, DORIPENEM, FENTANYL CITRATE, HEPARIN SODIUM, HETASTARCH, KETAMINE HYDROCHLORIDE, LEVETIRACETAM, MEROPENEM, NITROPRUSSIDE SODIUM, PACLITAXEL, PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM, TACROLIMUS, TRANEXAMIC ACID, and VANCOMYCIN HYDROCHLORIDE.

In addition new compatibility information is reported for over 20 existing drug monographs, including entries for CEFTOLOZANE AND TAZOBACTAM, IRINOTECAN HYDROCHLORIDE, TEDIZOLID PHOSPHATE, and SUGAMMADEX.

In this supplement we added new drug monographs for CEFTAZIDIME AND AVIBACTAM, CEFTOLOZANE AND TAZOBACTAM, and SUGAMMADEX.

Also, we added new stability information for these drugs:  AMPICILLIN SODIUM, LABETALOL HYDROCHLORIDE, PIPERACILLIN AND TAZOBACTAM, POLYMYXIN B SULFATE, and PROPAFENONE HYDROCHLORIDE.

In addition new compatibility information is reported for ESMOLOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE, and METOPROLOL HYDROCHLORIDE, each in combination with 14 different drugs. Overall, new compatibility information is included for over 90 unique drug pairs in this supplement.

In this supplement we added new drug monographs for DEFIBROTIDE SODIUM, CLEVIDIPINE, IPILIMUMAB, and POSACONAZOLE.

Also, we added new stability information for these drugs: AZACITIDINE, BENDAMUSTINE HYDROCHLORIDE, DEFEROXAMINE MESYLATE, DOXARUBICIN HYDROCHLORIDE, ERTAPENEM, GANCICLOVIR SODIUM, and MELPHALAN.

In addition new compatibility information is reported for LEVOFLOXACIN, MOXIFLOXACIN, NOREPINEPHRINE BITARTRATE, PIPERACILLIN AND TAZOBACTAM, TRAMADOL HYDROCHLORIDE, and VANCOMYCIN HYDROCHLORIDE.

In this supplement we added new drug monographs for CANGRELOR (including compatibility information with 99 drugs), and for TEDIZOLID (including compatibility information with 86 drugs). Also, we added new stability information for fifteen drugs: ABCIXIMAB, ALFENTANIL HYDROCHLORIDE, ALTEPLASE, AZITHROMYCIN DIHYCLATE, BUPIVACAINE LIPOSOME, CO-TRIMOXAZOLE, DAPTOMYCIN, DIGOXIN, ERTAPENEM, MICAFUNGIN SODIUM, MILRINONE LACTATE, PROPOFOL, QUINUPRISTIN AND DALFOPRISTIN, ROPIVACAINE HYDROCHLORIDE and ZICONOTIDE. In addition new compatibility information is reported for BUPIVACAINE LIPOSOME AND ZICONOTIDE.

In this supplement we added stability information for thirteen drugs: BETAMETHASONE SODIUM PHOSPHATE, CEFTAROLINE FOSAMIL, CETUXIMAB, COLISTIMETHATE SODIUM, ESOMEPRAZOLE SODIUM, GANCICLOVIR SODIUM, ISOPROTERENOL HYDROCHLORIDE, METOPROLOL TARTRATE, MICAFUNGIN SODIUM, MORPHINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE, SODIUM PHOSPHATE and VASOPRESSIN.

In addition new compatibility information is reported for over thirty drug combinations, including: BETAMETHASONE SODIUM PHOSPHATE, BLEOMYCIN SULFATE, CALCIUM GLUCONATE, DAPTOMYCIN, EPINEPHRINE HYDROCHLORIDE, FUROSEMIDE, KETOROLAC TROMETHAMINE, LEVOBUPIVACAINE, MORPHINE HYDROCHLORIDE, MAGNESIUM SULFATE, OXACILLIN SODIUM, PERITONEAL DIALYSIS SOLUTIONS, POTASSIUM PHOSPHATE, ROPIVACAINE HYDROCHLORIDE, and VANCOMYCIN HYDROCHLORIDE.

In this supplement we added stability information for BENDAMUSTINE HYDROCHLORIDE, CHLOROTHIAZIDE SODIUM, FLUMAZENIL, PHYTONADIONE, and TELAVANCIN.

In addition new compatibility information is reported for BUTORPHANOL TARTRATE, DEXAMETHASONE SODIUM PHOSPHATE, DIPHENHYDRAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE, ESOMEPRAZOLE SODIUM, FENTANYL CITRATE, FUROSEMIDE, GRANISETRON HYDROCHLORIDE, LORAZEPAM, METHADONE HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE, PIPERACILLIN AND TAZOBACTAM, VANCOMYCIN HYDROCHLORIDE, and VINCRISTINE SULFATE.

In this supplement we added two new drug monographs with stability and compatibility information for BENDAMUSTINE HYDROCHLORIDE and NALMEFENE HYDROCHLORIDE. In addition new compatibility information is reported for AMIODARONE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE, DEXAMETHASONE SODIUM PHOSPHATE, DOBUTAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE, HEPARIN SODIUM, INSULIN, REGULAR, KETAMINE HYDROCHLORIDE, METHADONE HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE, NITROPRUSSIDE SODIUM, and SUFENTAIL CITRATE. Lastly, we added new stability information to these drug monographs: AMSACRINE, BLEOMYCIN SULFATE, CLONIDINE HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE, FOSAPREPITANT DIMECLUMINE, and MEROPENEM.

In this supplement we added one new drug monograph with stability and compatibility information for CABAZITAXEL. In addition new compatibility information is reported for CISATRACURIUM BESYLATE with nine other drugs, DOXAPRAM HYDROCHLORIDE with twelve other drugs, in addition to compatibility reports for twenty-five different two-drug combinations. Lastly, we added new stability information to these drug monographs: ASCORBIC ACID, BEVACIZUMAB, BORTEZOMIB, CEFTRIAXONE SODIUM, CISATRACURIUM BESYLATE, DAPTOMYCIN, DOCETAXEL, DOXAPRAM HYDROCHLORIDE, EPINEPHRINE HYDROCHLORIDE, EPOPROSTENOL SODIUM, ESMOLOL HYDROCHLORIDE, MEROPENEM, OMEPRAZOLE SODIUM, OXALIPLATIN, PROCAINAMIDE HYDROCHLORIDE, TREPROSTINIL SODIUM, and VASOPRESSIN.

In this supplement we added three new drug monographs with stability and compatibility information for INSULIN GLARGINE, INSULIN GLULISINE, and ORITAVANCIN. In addition new compatibility information is reported for INSULIN ASPART with 47 other drugs, ORITAVANCIN with 37 other drugs, and ROCURONIUM BROMIDE with 20 other drugs. Lastly, we added new stability information to these drug monographs: AZATHIOPRINE SODIUM, CLONAZEPAM, DEXRAZOXANE, METHOHEXITAL SODIUM, MORPHINE HYDROCHLORIDE, TIROFIBAN HYDROCHLORIDE, and TRANEXAMIC ACID.

We added new compatibility information for CALCIUM CHLORIDE, EPINEPHRINE HYDROCHLORIDE, CONIVAPTAN, DOBUTAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE, FUROSEMIDE, HEPARIN SODIUM, TOTAL PARENTERAL NUTRITION SOLUTIONS with 46 drugs, and ALPROSTADIL with 13 drugs. In addition, we added new stability information to these drug monographs: ALPROSTADIL, BUSULFAN, DAPTOMYCIN, ESOMEPRAZOLE SODIUM, FILGRASTIM, FLUDARABINE PHOSPHATE, FOLIC ACID, HYDROCORTISONE SODIUM SUCCINATE, PENICILLLIN G SODIUM, RIFAMPIN, and TOTAL PARENTERAL NUTRITION SOLUTIONS.

We added new compatibility information for over 100 different parenteral drugs in combination with KETAMINE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE and MORPHINE SULFATE. In addition, we added new stability information to these drug monographs: ACETAZOLAMIDE SODIUM, ERTAPENEM, KETAMINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE, and ROCURONIUM BROMIDE.

We added new compatibility information for over 100 different parenteral combinations, including numerous entries for these monographs: ACETAMINOPHEN, CIPROFLOXACIN, DIMENHYDRINATE, and VANCOMYCIN HYDROCHLORIDE.

In addition, we added new stability information to these drug monographs: BORTEZOMIB, CIPROFLOXACIN, DIMENHYDRINATE, DOCETAXEL, EPIRUBICIN HYDROCHLORIDE, GENTAMICIN SULFATE, GRANISETRON HYDROCHLORIDE, HEPARIN SODIUM, HYDROMORPHONE HYDROCHLORIDE, MELPHALAN, NALOXONE HYDROCHLORIDE, NITROGLYCERIN, OCTREOTIDE ACETATE, PIPERACILLIN AND TAZOBACTAM, PROTAMINE SULFATE, TICARCILLIN DISODIUM-CLAVULANATE POTASSIUM, VANCOMYCIN HYDROCHLORIDE, and VECURONIUM BROMIDE.

We added new stability data to ten drug monographs, along with new information on over 50 different parenteral combinations, including entries in these monographs: AZACITIDINE, CEFAZOLIN SODIUM, CIPROFLOXACIN, CLOXACILLIN SODIUM, CYCLOSPORINE, KETAMINE HYDROCHLORIDE, MEROPENEM, METOCLOPRAMIDE HYDROCHLORIDE, MORPHINE SULFATE, NALOXONE HYDROCHLORIDE, PHENYTOIN SODIUM. RANITIDINE HYDROCHLORIDE, and VANCOMYCIN HYDROCHLORIDE

This update provides new drug monographs for BUPIVACAINE LIPOSOME and SODIUM GLYCOLATE. In addition new information on over 150 different parenteral combinations is included, including entries in these monographs: ADENOSINE ALPROSTADIL AMPHOTERICIN B LIPOSOME DEXMEDETOMIDINE NALOXONE HYDROCHLORIDE NICARDIPINE HYDROCHLORIDE PAPAVERINE HYDROCHLORIDE PHENTOLAMINE MESYLATE PIPERACILLIN AND TAZOBACTAM POTASSIUM PHOSPHATE VANCOMYCIN HYDROCHLORIDE Also included is the addition of 3,300 new drug combinations.

Included in this supplement are new drug monographs for IBUTILIDE FUMARATE and PERTUZUMAB. In addition we have included updates to the following existing monographs: ALDESLEUKIN AMPHOTERICIN B LIPOSOME CARBOPLATIN CEFEPIME HYDROCHLORIDE DILTIAZEM HYDROCHLORIDE ESMOLOL HYDROCHLORIDE MAGNESIUM SULFATE METOCLOPRAMIDE HYDROCHLORIDE MIDAZOLAM HYDROCHLORIDE PROPOFOL REMIFENTANIL HYDROCHLORIDE SODIUM CITRATE SODIUM BICARBONATE SUFENTANIL CITRATE TRAMADOL HYDROCHLORIDE TRASTUZUMAB.

Boxed Warning, REMS, and Prescribing and Access Restriction Drugs have been identified and highlighted. Included in this supplement are new drug monographs for PROCHLORPERAZINE MESYLATE, RITUXIMAB, SILDENAFIL CITRATE, and TEMSIROLIMUS. In addition we have included new compatibility information for ACETAMINOPHEN with ten parenteral drugs, along with revisions to the following existing monographs: BEVACIZUMAB, CARMUSTINE, DOBUTAMINE HYDROCHLORIDE, GENTAMICIN SULFATE, LEVOFLOXACIN, MICAFUNGIN SODIUM, OXYCODONE HYDROCHLORIDE, SODIUM BICARBONATE, SODIUM CITRATE, and VANCOMYCIN HYDROCHLORIDE.

Included in this supplement is a new drug monograph for CONIVAPTAN HYDROCHLORIDE. In addition we have included new compatibility information for SOTALOL HYDROCHLORIDE in combination with 32 other parenteral drugs, along with revisions to these existing monographs: CYTARABINE, DEXMEDETOMIDINE, EPOPROSTEROL SODIUM, FENTANYL CITRATE, GLOBULIN, IMMUNE (HUMAN), GLYCOPYRROLATE, HEPARIN SODIUM, INFLIXIMAB, MORPHINE SULFATE, TELAVANCIN, and VANCOMYCIN.

Included in this supplement are new drug monographs for BEVACIZUMAB and CLOFARABINE. In addition we have included new compatibility and stability information for these existing monographs: ACETAMINOPHEN, BORTEZOMIB, CLINDAMYCIN PHPOSPHATE, DEXMEDETOMIDINE, FOSPHENYTOIN, INSULIN ASPART, INSULIN LISPRO, KETAMINE HYDROCHLORIDE, KETOPROFEN, KETOROLAC TROMETHAMINE, MIDAZOLAM HYDROCHLORIDE, PEMETREXED PROPOFOL, TRAMADOL HYDROCHLORIDE, TROPHAMINE, and VANCOMYCIN HYDROOCHLORIDE.

Included in this supplement is a new drug monograph for TRASTUZUMAB. In addition we have included new compatibility and stability information for these existing monographs: ACETAMINOPHEN, CALCIUM CHLORIDE, CALCIUM GLUCONATE, CEFTAROLINE FOSAMIL, DOBUTAMINE HYDROCHLORIDE, DOCETAXEL, LEVOFLOXACIN, SODIUM BICARBONATE, and VINORELBINE TARTRATE.

In this supplement is a new drug monograph for LEVOCARNITINE. In addition we have included new compatibility and stability information for these existing monographs: AMOXICILLIN-CLAVULANATE, CIPROFLOXACIN, HEPARIN SODIUM, HYDROMORPHONE HYDROCHLORIDE, MORPHINE SULFATE NICARDIPINE HYDROCHLORIDE, OCTREOTIDE LACTATE, and PANTOPRAZOLE SODIUM.

Included in this supplement is a new drug monograph for KETOPROFEN. In addition we have included new information on the compatibility of ACETAMINOPHEN with twenty-eight other parenteral drugs. We have also added new compatibility and stability information to these existing monographs: AMIODARONE HYDROCHLORIDE, CYCLOSPORINE, ESMOLOL HYDROCHLORIDE, HEPARIN SODIUM, INSULIN, REGULAR, LABETALOL HYDROCHLORIDE, LEVOTHYROXINE SODIUM, NITROGLYCERIN, NITROPRUSSIDE SODIUM, NOREPINEPHRINE BITARTRATE, PANCURONIUM BROMIDE, PHENYLEPHRINE HYDROCHLORIDE, TERBUTALINE SUFATE, and VECURONIUM BROMIDE.

Included in this supplement is a new drug monograph for TELAVANCIN that reports on its compatibility with 52 other parenteral drugs. In addition we have added new compatibility and stability information to these existing monographs: DEXRAZOXANE, DORIPENEM, DROPERIDOL, ERTAPENEM, FUROSEMIDE, IMIPENEM, INSULIN, METHOHEXITAL SODIUM, NOREPINEPHRINE BITARTRATE, PHENYLEPHRINE HYCRODHLORIDE, SODIUM BICARBONATE and VASOPRESSIN.

Included in this supplement are new drug monographs for these parenteral drugs: ACETAMINOPHEN, LEVETIRACETAM, ARGININE HYDROCHLORIDE, MORPHINE TARTRATE, CEFTAROLINE FOSAMIL, PAMIDRONATE DISODIUM, EDETATE CALCIUM DISODIUM, and SODIUM THIOSULFATE. In addition we have added new compatibility and stability information to these existing monographs: ALPROSTADIL, AMIODARONE HYDROCHLORIDE, AMPHOTERICIN B, BUPIVACAINE HYDROCHLORIDE, CEFAZOLIN SODIUM, DILTIAZEM HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE, FENTANYL CITRATE, GENTAMICIN SULFATE, HEPARIN SODIUM KETAMINE HYDROCHLORIDE, MICAFUNGIN, MORPHINE SULFATE, ONDANSETRON HYDROCHLORIDE, SODIUM BICARBONATE, SODIUM CITRATE, VANCOMYCIN HYDROCHLORIDE, ZICONOTIDE, and VASOPRESSIN.

Included in this supplement are new drug monographs for these parenteral drugs: HYOSCINE BUTYLBROMIDE SODIUM CITRATE TEICOPLANIN In addition we have added new compatibility and stability information to these existing monographs: AMIKACIN SULFATE, CASPOFUNGIN ACETATE, CIPROFLOXACIN, DAPTOMYCIN, FLUOROURACIL, HALOPERIDOL LACTATE, HEPARIN SODIUM, KETAMINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE, LINEZOLID, MORPHINE SULFATE, TRAMADOL HYDROCHLORIDE, and VANCOMYCIN HYDROCHLORIDE.

Included in this supplement are new drug monographs for these parenteral drugs: ACETYLCYSTEINE, CLINIMIX INJECTIONS, OFATUMUMAB, ROMIDEPSIN, and TELAVANCIN. In addition we have added new compatibility and stability information to these existing monographs: AMIODARONE HYDROCHLORIDE, CEFTAZIDIME, DOBUTAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE, FUROSEMIDE, HYDROMORPHONE HYDROCHLORIDE, NITROGLYCERINE, PANCURONIUM BROMIDE, PIPERACILLIN AND TAZOBACTAM, and SODIUM BICARBONATE.

Included in this supplement are new drug monographs for these parenteral drugs: CETUXIMAB, INFLIXIMAB, PANITUMUMAB, and SOTALOL HYDROCHLORIDE. In addition we have added new compatibility and stability information to these existing monographs: DAPTOMYCIN, DILTIAZEM HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE, DORIPENEM, EPINEPHRINE HYDROCHLORIDE, FUROSEMIDE, MAGNESIUM SULFATE, MESNA, NITROPRUSSIDE SODIUM, SODIUM BICARBONATE, and TERBUTALINE SULFATE.

This update includes our first original research for the drugs: ATROPINE SULFATE and PANCURONIUM BROMIDE. This information can only be found in the King Guide. Also, included in this supplement are new drug monographs for these parenteral drugs: BORTEZOMIB and IRON SUCROSE. In addition we have added new compatibility and stability information to these existing monographs: ATROPINE SULFATE, CEFEPIME HYDROCHLORIDE, DIMENHYDRINATE, GANCICLOVIR, HALOPERIDOL LACTATE, INSULIN, REGULAR, IRONOTECAN HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE, MORPHINE HYDROCHLORIDE, MORPHINE SULFATE, NOREPINEPHRINE BITARTRATE, RANITIDINE HYDROCHLORIDE, SODIUM BICARBONATE, TACROLIMUS, TRAMADOL and TRANEXAMIC ACID.

Included in this supplement are new drug monographs for these parenteral drugs: ALEMTUZUMAB, AMPHOTERICIN B LIPOSOME, IBUPROFEN, and INSULIN LISPRO. In addition we have added new compatibility and stability information to these existing monographs: ARIPIPRAZOLE, BUSULFAN, DALTEPARIN SODIUM, EPTIFIBATIDE, METOPROLOL TARTRATE, NEOSTIGMINE METHYLSULFATE, NESIRITIDE, OXALIPLATIN, PALONOSETRON HYDROCHLORIDE, PERITONEAL DIALYSIS SOLUTIONS, PROPOFOL, and VANCOMYCIN HYDROCHLORIDE.

We have added new compatibility and stability information to these monographs: ACYCLOVIR SODIUM, AMIODARONE, CAFFEINE CITRATE, CYCLOSPORINE, LEVOFLOXACIN, MEROPENEM, and VANCOMYCIN.

We have added new compatibility and stability information to these monographs: ACYCLOVIR SODIUM, AMIODARONE, CAFFEINE CITRATE, CYCLOSPORINE, LEVOFLOXACIN, MEROPENEM, and VANCOMYCIN.

We have added new monographs for these parenteral products: ESOMEPRAZOLE SODIUM, MOXIFLOXACIN HYDROCHLORIDE, and ZICONOTIDE. We have also added new compatibility and stability information to these monographs: AMIODARONE HYDROCHLORIDE, ATROPINE SULFATE, MORPHINE SULFATE, MORPHINE HYDROCHLORIDE, OCTREOTIDE ACETATE, OMEPRAZOLE SODIUM, PRALIDOXIME CHLORIDE, and TRAMADOL HYDROCHLORIDE.

We have added stability and compatibility information for these parenteral products: ANIDULAFUNGIN, NOREPINEPHRINE BITARTRATE, and SUCCINYLCHOLINE CHLORIDE. The new information for ANIDULAFUNGIN includes admixture compatibility data in combination with 77 different parenteral products.

FAMOTIDINE, HEPARIN SODIUM, LIDOCAINE HYDROCHLORIDE, MICAFUNGIN SODIUM, PAPAVERINE HYDROCHLORIDE, SODIUM BICARBONATE, and TIGECYCLINE. The new information for MICAFUNGIN includes admixture compatibility data for MICAFUNGIN in combination with 49 different parenteral products. And, a new monograph for TIGECYCLINE has also been included in the enclosed Supplement.

We have added stability and compatibility information for these parenteral products: CASPOFUNGIN ACETATE, METRONIDAZOLE, and PALONOSETRON HYDROCHLORIDE. Included are the results of admixtures compatibility studies of these three parenterals in combination with over 80 other drug products.

We have added stability and compatibility information for these drug products: DORIPENEM, EPIRUBICIN, LEVOBUPIVACAINE, and VORICONAZOLE. We are also reporting new results of stability studies for DAPTOMYCIN.

We have added stability information for one new drug product: PANTOPRAZOLE. We are also reporting the results of compatibility studies for PANTOPRAZOLE in admixture with 90 parenteral products including: CASPOFUNGIN ACETATE, CIPROPLOXACIN, ENALAPRILAT, FLUCONAZOLE, LEVOFLOXACIN, MEROPENEM, PROPOFOL, VASOPRESSIN, and ZIDOVUDINE. Also included in the enclosed supplement is additional compatibility information for CEFTRIAXONE used with calcium-containing products.

We have updated important new medication safety information on CEFTRIAXONE SODIUM, as reported by the U.S. Food and Drug Administration. We have added stability and compatibility information for one new drug product: CELLCEPT®. Also included is compatibility information for CASPOFUNGIN ACETATE, ALFENTANIL HYDROCHLORIDE, and CEFTAZIDIME in combination with numerous other parenteral drugs.

We have added important new medication safety information on CEFTRIAXONE SODIUM, as reported by the U.S. Food and Drug Administration. We have also added stability and compatibility information for three new drug products: ARIPIPRAZOLE, CASPOFUNGIN ACETATE, and ROPIVACAINE HYDROCHLORIDE. Also included in this update are compatibility information for CEFEPIME, GANCICLOVIR, KETAMINE, KETOROLAC, and NESIRITIDE.

We have added compatibility information for one new drug product: OXALIPLATIN. Included in this new drug monograph is compatibility information for over 50 different parenteral drug combinations, including: Bumetanide, Docetaxel, Dolasetron Mesylate, Enalaprilat, Gemcitabine Hydrochloride, Leucovorin Calcium, Ondansetron Hydrochloride, Paclitaxel, Ranitidine Hydrochloride, Topotecan Hydrochloride, and Verapamil Hydrochloride. The results of stability studies on PALONOSETRON HYDROCHLORIDE with CISPLATIN, CARBOPLATIN, METOCLOPRAMIDE HYDROCHLORIDE, and PROMETHAZINE HYDROCHLORIDE are also included in our 2007 Summer Supplement.

We have added compatibility information for two new drug products: Piperacillin and Tazobactam, and Pemetrexed. Included in these two new drug monographs are compatibility information for over 80 different parenteral drug combinations, including: amifostine, amikacin, aztreonam, carboplatin, ciprofloxacin, dexrazoxane, docetaxel, doxorubicin, gentamicin, granisetron, irinotecan, ranitidine, topotecan, and zidovudine.

We have added compatibility information for two new drugs: Nesiritide in combination with 30 different drugs, and infusion stability data for Insulin Aspart. In addition we have provided additional information for these existing drug monographs: Oxytocin, Palonosetron, Dacarbazine, Cefuroxime, and Leucovorin Calcium.

We have added compatibility information for Lansoprazole in combination with seventy-eight different parenteral products including the following: Acyclovir, Gemcitabine, Alatrofloxacin, Gentamicin, Ceftriaxone, Labetalol, Cyclosporine, Midazolam, Droperidol, Morphine, Enalaprilat, Nicardipine, Etoposide, Paclitaxel, Famotidine, Ranitidine, Fentanyl, Vinorelbine, Ganciclovir, and Zidovudine.

We have added compatibility information for a new drug, Lansoprazole. Also included are new data on the compatibility and stability of these drugs: Clonidine Hydrochloride, Fentanyl Citrate, Morphine Sulfate, Hydralazine Hydrochloride, and Vasopressin.

We have added a new drug monograph, DEXMEDETOMIDINE HYDROCHLORIDE (PRECEDEX®), in this supplement. Over 90 different drugs were tested with this drug, including: Alfentanil, Amiodarone, Azithromycin, Aztreonam, Bretylium, Cefepime, Cimetidine, Dobutamine, Dolasetron, Enalaprilat, Esmolol, Famotidine, Gatifloxacin, Inamrinone, Ketorolac, Linezolid, Milrinone, Ofloxacin, Ondansetron, Propofol, Ranitidine, Sufentanil, Vancomycin, and Verapamil.

We have added a new drug monograph, Tramadol Hydrochloride, in this supplement. Also included is new information for 46 different drugs including entries for these parenteral products: Argatroban, Cidofovir, Clonidine Hydrochloride, Dolasetron Mesylate, Doxorubicin Hydrochloride, Droperidol, Fentanyl Citrate, Gentamicin Sulfate, Ketamine Hydrochloride, Ketorolac Tromethamine, Levofloxacin, Lorazepam, Morphine Sulfate, Ondandestron Hydrochloride, Palonosetron Hydrochloride, Vancomycin Hydrochloride, and Zidovudine.

Included in this supplement are new information for Bivalirudin, Fenoldopam Mesylate, and Teniposide in combination with dozens of other parenteral drug products. In addition, we have added monographs for Codeine Sulfate, Ammonium Chloride, and Amobarbital.

Included in this Supplement are compatibility data for one new drug monograph, Drotrecogin Alfa, in combination with thirty-four different parenteral medications. Also included are compatibility data for Argatroban in combination with total parenteral nutrition solutions and with these drugs: Amiodarone hydrochloride, Furosemide, Fenoldopam Mesylate, Lidocaine Hydrochloride, Milrinone Lactate, Nitroglycerin, Nitroprusside Sodium, and Vasopressin.

Included in this Supplement are compatibility data for two new drug monographs: Daptomycin and Palonosetron Hydrochloride. In addition we have added new information to these existing monographs: Co-Trimoxazole, Fluorouracil, Furosemide, Inamrinone Lactate, Levofloxacin, Nitroglycerin, Norepinephrine Bitartrate, Ondansetron Hydrochloride, and Potassium Phosphate.